Instil Bio, Inc.
General ticker "TIL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $108.8M (TTM average)
Instil Bio, Inc. does not follow the US Stock Market performance with the rate: -21.8%.
Estimated limits based on current volatility of 1.5%: low 7.60$, high 7.83$
Factors to consider:
- Total employees count: 17 (+21.4%) as of 2025
- Top business risk factors: Operational and conduct risks, Inability to raise capital, Clinical trial failure, Regulatory and compliance, Manufacturing supply issues
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.71$, 12.40$]
- 2026-12-31 to 2027-12-31 estimated range: [2.35$, 7.87$]
Financial Metrics affecting the TIL estimates:
- Negative: with PPE of -1.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -49.34 <= 0.28
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 34.33 > -0.64
- Negative: Interest expense per share per price, % of 7.85 > 3.34
- Negative: negative Industry operating cash flow (median)
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term TIL quotes
Long-term TIL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $159.17MM | $73.54MM | $78.58MM |
| Operating Income | $-159.17MM | $-73.54MM | $-78.58MM |
| Non-Operating Income | $3.08MM | $-0.59MM | $7.00MM |
| Interest Expense | $5.21MM | $8.99MM | $5.83MM |
| R&D Expense | $39.60MM | $21.84MM | $34.74MM |
| Income(Loss) | $-156.09MM | $-74.14MM | $-71.58MM |
| Net Income(Loss)* | $-156.09MM | $-74.14MM | $-71.58MM |
| Stockholders Equity | $225.83MM | $169.44MM | $113.87MM |
| Assets | $325.63MM | $263.57MM | $203.52MM |
| Operating Cash Flow | $-82.03MM | $-55.70MM | $-36.62MM |
| Capital expenditure | $20.66MM | $10.00MM | $0.00MM |
| Investing Cash Flow | $41.13MM | $53.97MM | $25.48MM |
| Financing Cash Flow | $8.08MM | $1.75MM | $7.29MM |
| Earnings Per Share** | $-24.00 | $-11.39 | $-10.74 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.